TA reports consulting, advisory role or honoraria, or both, from Amgen, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Chugai, Clovis, Gritstone Oncology, GlaxoSmithKline, Haliodx, Kaleido Biosciences, Merck & Co, Pierre Fabre, Roche/Ventana, Sanofi, Transgene, Seagen, and Servier; and compensation for travel, accommodation, and expenses from Roche/Genentech, Merck Sharp & Dohme (MSD) & Co, and Bristol-Myers Squibb. LAD Jr reports membership on the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics; honoraria for consulting, advisory role to PGDx, 4Paws, and Neophore; uncompensated consulting, advisory role for MSD; research funding to the institution for clinical trials from MSD; patents for circulating tumour DNA analyses and mismatch repair deficiency for diagnosis and therapy with checkpoint blockade from Johns Hopkins University, which is licensed to PGDx and Qiagen. Some licenses and relationships are associated with equity or royalty payments directly to Johns Hopkins and LAD Jr. LAD Jr has equity in 4Paws, PGDx, Jounce Therapeutics, Thrive Earlier Detection, and Neophore. His spouse holds equity in Amgen. The terms of all these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. K-KS reports consulting, advisory role or honoraria, or both, including compensation for travel, accommodation, and expenses from Bayer, Bristol-Myers Squibb, Guardant Health, Daiichi-Sankyo, Innovent Biologics, Merck KGaA, MSD, Mirati Therapeutics, Roche, and Servier; and Institutional Funding for Research from Adaptimmune Therapeutics, AstraZeneca, Merck KGaA, MSD and Roche, and Bristol-Myers Squibb.